There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > MMP-9


MMP-9 Molecule Information

Name:Matrix metalloproteinase 9
Target Synonym:92 kDa gelatinase;Gelatinase B;GELB;82 kDa matrix metalloproteinase-9;Matrix metalloproteinase-9;92 kDa type IV collagenase;CLG4B;MMP9;67 kDa matrix metalloproteinase-9;MMP-9
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:15
Lastest Research Phase:NDA Filing

MMP-9 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
MM9-H5221 Human Human MMP-9 Protein, His Tag

MMP-9 Molecule Synonym Name


MMP-9 Molecule Background

Matrix metallopeptidase 9 (MMP-9) is also known as 92 kDa type IV collagenase, 92 kDa gelatinase or gelatinase B (GELB), CLG4B, is secreted from neutrophils, macrophages, and a number of transformed cells, and is the most complex family member in terms of domain structure and regulation of its activity. . Structurally, MMP9 maybe be divided into five distinct domains: a prodomain which is cleaved upon activation, a gelatinbinding domain consisting of three contiguous fibronectin type II units, a catalytic domain containing the zinc binding site, a prolinerich linker region, and a carboxyl terminal hemopexinlike domain. This enzyme degrades various substrates including gelatin, collagen types IV and V, and elastin. MMP9 is involved in a variety of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis, and be regarded as a potential therapeutic target.

MMP-9 References

MMP-9 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Abametapir BRN-0123183; DFD-11; HA-44; Ha44 Gel Approved Hatchtech XEGLYZE fda DR REDDYS LABS SA 2020-07-24 Pediculosis Details

MMP-9 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
AQU-005 AQU-005; NMAQU-005; NM-AQU-005 Phase Ⅰ Aquilus Pharmaceuticals, NeuroMax Neuropathic pain Details
RBx-10017609 Phase Ⅱ Sun Pharmaceutical, GlaxoSmithKline Chronic obstructive pulmonary disease (COPD) Details
ABT-518 ABT 518 Phase Ⅰ Abbvie Solid tumours Details
SD-7300 Phase Ⅰ Pfizer Solid tumours Details
PG-116800 PG-116800; PG-530742; PGE-7113313,PG116800; PG530742; PGE7113313,PG 116800; PG 530742; PGE 7113313 Phase Ⅱ Procter & Gamble Osteoarthritis (OA), Heart failure, Myocardial infarction (MI) Details
Andecaliximab GS-5745 Phase Ⅲ Gilead Gastric cancer Details
AZD-1236 AZD-1236 Phase Ⅱ AstraZeneca Chronic obstructive pulmonary disease (COPD) Details
Incyclinide CMT-3; COL-3; NSC-683551 Phase Ⅱ Galderma Acne, Rosacea Details
S-3304 S-3304 Phase Ⅱ Shionogi Solid tumours Details
Tanomastat BAY-12-9566 Phase Ⅲ Bayer Small cell lung cancer (SCLC), Non small cell lung cancer (NSCLC), Ovarian cancer, Pancreatic cancer Details
AE-941 AE-941; NSC-706456 Phase Ⅲ AEterna Zentaris, Ferrer, Pfizer, National Cancer Institute, Alcon Non small cell lung cancer (NSCLC), Renal carcinoma Details
RS-130830 RS-130830; CTS-1027; RO-1130830,RS130830,CTS1027,RO1130830 Phase Ⅱ Roche, Conatus Pharmaceutical Arthritis, HCV infection Details
CP-471358 CP-471358 Phase Ⅰ Pfizer Solid tumours Details
Rebimastat BMS-275291; D-2163 Phase Ⅲ Celltech, Bristol-Myers Squibb Non small cell lung cancer (NSCLC) Details

This web search service is supported by Google Inc.